Michael Burkes Brophy Sells 691 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 691 shares of the firm’s stock in a transaction on Friday, October 25th. The stock was sold at an average price of $118.81, for a total value of $82,097.71. Following the sale, the chief financial officer now directly owns 72,709 shares of the company’s stock, valued at approximately $8,638,556.29. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, October 23rd, Michael Burkes Brophy sold 496 shares of Natera stock. The stock was sold at an average price of $119.09, for a total value of $59,068.64.
• On Monday, October 21st, Michael Burkes Brophy sold 608 shares of Natera stock. The stock was sold at an average price of $120.76, for a total value of $73,422.08.
• On Wednesday, July 31st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The stock was sold at an average price of $99.65, for a total transaction of $185,946.90.
• On Monday, July 29th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The shares were sold at an average price of $102.77, for a total transaction of $127,229.26.

Natera Trading Down 1.3 %

Shares of NASDAQ:NTRA opened at $117.67 on Friday. Natera, Inc. has a 52 week low of $36.90 and a 52 week high of $133.54. The company’s 50 day moving average is $123.24 and its two-hundred day moving average is $111.24. The company has a market cap of $14.55 billion, a PE ratio of -48.03 and a beta of 1.53. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.39. The firm had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. Natera’s revenue for the quarter was up 58.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.97) earnings per share. Equities analysts predict that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

Hedge funds and other institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC boosted its holdings in Natera by 1,073.1% in the second quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company’s stock valued at $7,118,000 after purchasing an additional 60,127 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Natera by 15.1% in the 1st quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company’s stock valued at $6,810,000 after buying an additional 9,781 shares in the last quarter. Natixis purchased a new position in shares of Natera in the 1st quarter valued at $758,000. Allspring Global Investments Holdings LLC raised its stake in Natera by 19.9% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 863,406 shares of the medical research company’s stock worth $78,967,000 after acquiring an additional 143,246 shares in the last quarter. Finally, Baader Bank Aktiengesellschaft acquired a new stake in Natera during the 2nd quarter worth $478,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Morgan Stanley lifted their target price on shares of Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. Piper Sandler reaffirmed an “overweight” rating and issued a $150.00 price objective on shares of Natera in a research note on Friday, September 13th. UBS Group cut their price objective on Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a report on Friday, August 9th. TD Cowen raised their target price on Natera from $137.00 to $145.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, BTIG Research boosted their price target on shares of Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $124.44.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.